Evaluation of the Sphingolipid Metabolite S1P as a Novel Biomarker in Food Allergy

• Conditions: Food Allergy; Anaphylaxis

• Registration Number: NCT01776489
• Lead Sponsor: Medical University of Vienna

Brief Summary

Food allergies represent an increasing health concern in the industrialized countries and especially affect pediatric patients. In this population adverse reactions against food compounds can lead to anaphylactic reactions. Despite substantial research efforts, clinical markers predicting disease severity and symptoms are missing to date.

Recent studies have revealed that sphingolipids, especially sphingosine-1-phosphate (S1P), play an essential role in allergy. It was reported that asthmatic patients have higher S1P levels in bronchiallavage fluids after allergen challenge. First experimental studies revealed a correlation of S1P and the outcome of anaphylaxis. Furthermore, we have shown in our recent mouse study that S1P homeostasis is pivotal for food allergy induction and effector cell response. Therefore, it is the aim of the presented pilot project to evaluate whether S1P serum titers are altered in food allergic children and if the S1P levels correlate with the outcome of anaphylaxis during double blind placebo controlled food challenges (DBPCFCs).

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2011-12
• Study First Submitted: 2013-01-21
• Study First Submitted QC: 2013-01-23
• Study First Posted: 2013-01-28
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-09
• Last Update Posted: 2015-12-11
• Primary Completion: 2017-01
• Study Completion: 2017-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• Patients between 1-17 years who have been reported to suffer from food allergic reactions and who are subjected to DBPCFC or open provocation
• Patients who are diagnosed by elevated allergen specific IgE and/or positive skin prick testing
• Willingness to participate in the study

Read More

Exclusion Criteria

• Refusal to participate in the study
• Non-IgE-mediated food allergy

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
S1P in allergic and non-allergic patients before and after challenge	up to 3 years	The primary endpoint of this study is the measurement of S1P in allergic and non-allergic patients before and after challenge.

Secondary Outcome Measures

Name	Time	Method
Evaluation of allergic mediators and correlation with S1P levels	up to 3 years	Evaluation of allergic mediators like histamine, human mast cell tryptase and eosinophil cationic protein and correlate these results with the levels of S1P within the group and between allergic and non-allergic patients

Trial Locations

Locations (1)

Medical University Vienna, Department of Pediatrics and Adolescent Medicine; 🇦🇹 Vienna, Austria